Mevalonate pathway-triggered phase transition of injectable hydrogel for cholesterol-downregulated therapy of osteoarthritis.

ABSTRACT: Dysregulation of mevalonate pathway, an essential metabolic route involving coenzyme A (CoASH) and cholesterol, contributes significantly to escalating cartilage degradation. Existing treatments rely on the simvastatin delivery via tunable sol-gel transition mechanisms of injectable hydrogel. However, those methods suffer from lack of controllable drug release by selective phase transition under distinct disease microenvironment. Herein, we developed an aberrant lipid metabolism microenvironment-activated phase transition (normal condition: gel-gel, abnormal condition: gel-sol) with targeted drug release for synergistic treatment of osteoarthritis (OA). Naked-eye diagnosis and therapy of OA through cholesterol downregulation using an injectable hydrogel were based on the simvastatin

SUBMITTER: Robby AI 

PROVIDER: S-EPMC12269283 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature